NYSE
$117.40▼ 0.96%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.34BShares out 45.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.8Pre-market26.10.08 19:158-KKey event#●●●#●●●#●●●
HAEMONETICS CORPBullish
Haemonetics announced that CSL Plasma expects to complete the rollout of the company's NexSys PCS devices and disposables across all its U.S. plasma collection centers by the end of 2027. The company is maintaining its current fiscal 2027 guidance and plans to provide an update on the agreement's financial impact during its second fiscal quarter earnings call in November 2026.…more
$117.40-0.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18Pre-market26.08.18 19:038-KKey event
HAEMONETICS CORP
Haemonetics entered into a non-exclusive supply agreement with CSL Plasma on August 14, 2026, for its NexSys PCS devices and related disposables. As the agreement contains no minimum purchase commitments, the company is not updating its fiscal 2027 guidance at this time and will provide a financial impact update during its second fiscal quarter earnings call in November 2026.…more
$117.40-0.96%vs prev closeView filingShare - 8.12Regular26.08.13 02:29SCHEDULE 13G/AOwnership
HAEMONETICS CORP
AQR Capital Management has filed a Schedule 13G/A amendment regarding its beneficial ownership in Haemonetics Corp. This filing serves as an official update on the firm's equity position in the company.…more
$117.40-0.96%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoAfter-hours26.10.20 05:16Bullish#●●●#●●●#●●●
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System…more
Haemonetics announced that it has received FDA approval for its PerQseal Elite vascular closure system designed for large-bore arterial procedures. This approval strengthens the company's portfolio of closure devices for structural heart and endovascular procedures in the U.S. market.…more
$117.40-0.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Regular26.10.09 02:04
●●●●●●●● ●●●●● ●●●●●●
Haemonetics shares surged after CSL Plasma announced plans to deploy the company's devices across all its U.S. collection centers by 2027. The company maintained its fiscal 2027 guidance as it awaits further details on the financial impact of the expanded partnership.…more
$117.40-0.96%vs prev closeShareBenzinga - 8.18Pre-market26.08.18 19:15
●●●●●●●● ●●●●● ●●●●●●
Haemonetics will supply its NexSys PCS devices and disposables to CSL Plasma under a non-exclusive agreement without minimum purchase commitments. As the scope and timing remain uncertain, the company has not updated its fiscal 2027 guidance.…more
$117.40-0.96%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report